## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($457.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. HCA Healthcare (NYSE: HCA) appoints Virginia Tenpenny to lead community engagement**
- Source: Stock Titan | 20251209T133231 | Bullish | Relevance: 99%
- HCA Healthcare has appointed Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny, who has over two decades of experience in corporate community impact, will lead the company's community engagement strategy, succeeding the retiring Joanne Pulles. This role oversees social and charitable investments, colleague giving, community outreach, and strategic partnerships.

**2. Daiwa Securities Group Inc. Decreases Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251210T150832 | Somewhat-Bullish | Relevance: 99%
- Daiwa Securities Group Inc. reduced its stake in HCA Healthcare, Inc. (NYSE:HCA) by 5.3% in Q2, bringing its total holdings to 38,469 shares valued at $14.74 million. This comes as HCA Healthcare reported strong Q3 earnings, beating analyst expectations, and had multiple analysts raise their price targets, resulting in a "Moderate Buy" consensus. An HCA executive also significantly decreased his personal holdings in the company.

**3. HCA taps new VP of community engagement**
- Source: Healthcare Dive | 20251209T154515 | Bullish | Relevance: 99%
-  HCA Healthcare has appointed Virginia Tenpenny as its new vice president of community engagement, overseeing charitable investments, outreach, and strategic partnerships. Tenpenny will join HCA on January 12, replacing Joanne Pulles, who is retiring after 26 years. In her new role, Tenpenny will build on HCA's significant community contributions, which exceeded $48.5 million in enterprise giving and over $18 million from employee matching funds in 2024.

**4. HighVista Strategies LLC Buys New Stake in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251211T130842 | Bullish | Relevance: 99%
-  HighVista Strategies LLC has acquired a new position in HCA Healthcare, Inc. (NYSE:HCA) during the second quarter, purchasing 3,100 shares valued at approximately $1.19 million. This move is part of broader institutional interest, with Norges Bank also buying a significant $1.15 billion stake, bringing total institutional ownership to about 62.73%. The company reported strong Q2 earnings, beating expectations with an EPS of $6.96 and revenue of $19.16 billion, leading to several analyst price target upgrades and a "Moderate Buy" consensus rating.

**5. State Street Corp Sells 191,043 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251210T115530 | Neutral | Relevance: 98%
-  State Street Corp reduced its stake in HCA Healthcare, Inc. by 2.3% in the second quarter, selling 191,043 shares and now owning 7,956,663 shares valued at over $3 billion. Other institutional investors have also adjusted their positions, while an EVP at HCA Healthcare sold a significant number of shares in November. The article also provides financial details for HCA Healthcare, including recent earnings, dividends, and analyst ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.2x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $112.9B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.2 |
| Current P/E | 17.5 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.2% to -1.9% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.23x) but short-term weakness (below SMA20). MACD histogram bearish (-4.24), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.93% (CS: 17) | Neutral |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | -4.24 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.233x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $482.35
- **Stop Loss:** $457.75 (5.1% risk)
- **Target:** $506.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $27,011.60
- **Portfolio %:** 27.01%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*